Companies

US-based Adagio Therapeutics gives Biocon Biologics licence to make antibody treatment for Covid-19

Our Bureau Bengaluru | Updated on July 26, 2021

Data indicates that the antibody could provide rapid and durable protection against Covid-19 for up to one year

The US-based Adagio Therapeutics has granted Biocon Biologics Ltd., a biosimilars company and a subsidiary of Biocon Ltd, an exclusive licence to manufacture and commercialise an antibody treatment based on ADG20 for India and select emerging markets.

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of Covid-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge, a statement from the company said on Monday.

The statement said initial data indicates that ADG20, Adagio’s lead clinical development candidate, could provide both rapid and durable protection against Covid-19 for up to one year. This could make it an ideal agent to prevent infections and significantly reduce Covid-19 related hospitalisations and death. With its potential to address resistant variants, including the Delta variant, and its ability to be administered easily as a single, intramuscular injection in the outpatient setting, ADG20 is uniquely poised to address the current need for an effective, safe and convenient therapy for Covid-19.

Kiran Mazumdar-Shaw, the executive chairperson of Biocon Biologics Ltd, said: “This partnership with Adagio aligns our joint vision of bringing superior biologic therapies to millions of patients in low and middle-income countries. Vaccines alone will not protect and make the world safer. Biologic therapies that arrest the virus in its path of devastation is a necessity for sustainable protection and safety.”

"We believe that Covid-19 will become an endemic disease requiring a variety of effective, safe and convenient treatment and prevention options for years to come," the statement said.

Published on July 26, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like